AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced Monday. The Britain based pharma giant said the expanded savings ...
More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says. In 2024, GlaxoSmithKline withdrew Flovent from the market.
Starting June 1, 2024, eligible patients will pay no more than $35 per month for the following AstraZeneca inhalers: Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort. The savings ...
The program automatically reduces the cost of the inhaler at the pharmacy for eligible patients with commercial insurance. Out-of-pocket costs for Boehringer Ingelheim asthma and chronic obstructive ...
Inhalers that combine providing immediate relief with a longer-term preventative effect are already recommended as the standard treatment for mild asthma among people aged 12 and above in the UK, US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results